Pharmaceutical company, Novo Nordisk, declares its standing superior to that of Eli Lilly.

Novo Nordisk asserts that using Wegovy can potentially lower the risk of heart attacks and mortality by 57% over Eli Lilly's Tirzepatide.

, and Administrator

2025 September 15 . 7:28 PM

1 min read

Pharmaceutical giant Novo Nordisk declares their success surpassing that of Eli Lilly.

Pharmaceutical company, Novo Nordisk, declares its standing superior to that of Eli Lilly.

In the competitive landscape of pharmaceutical companies, Danish firm Novo Nordisk is making a significant impact, particularly in relation to its key rival, Eli Lilly. This assertion comes following Novo Nordisk's presentation of further data for its obesity drug, Wegovy (Semaglutid), at a specialist conference in Madrid.

The new data, presented at the congress of the European Society of Cardiology (ESC), offers attractive entry points for long-term investors in Novo Nordisk's stock (WKN: A3EU6F). The study, which focused on obese individuals with cardiovascular diseases, revealed that Wegovy reduced the risk of heart attack, stroke, or death by 57% compared to Eli Lilly's Tirzepatide-based medication, Mounjaro.

Ludovic Helfgott, Novo Nordisk's Executive Vice President, stated that the results confirm that Semaglutid is the only available GLP-1 based medication with proven cardiovascular benefits for people with obesity and cardiovascular diseases without diabetes. This finding adds to the growing body of evidence that the heart-protective benefits of Wegovy are specific to the Semaglutid molecule.

Meanwhile, the main manufacturer of Mounjaro, listed on the German stock market, is Eli Lilly. The comparison between the two potential stocks has led to a significant trend being drawn, with some likening Novo Nordisk's stock to that of Palantir.

Elsewhere, Camurus received positive news, potentially signaling the next approval for a stock that bulls are optimistic about. However, Heidelberg Pharma and Telix experienced a share price drop following the rejection of an approval.

It is important to note that the publisher and author hold positions in Novo Nordisk, which could benefit from positive price developments due to the publication. As always, investors are encouraged to conduct their own research and consider their own investment objectives and risk tolerance before making investment decisions.